Shoroq Aljuaid

Board-certified Clinical Pharmacist (Saudi Board in Adult Internal Medicine) with comprehensive residency training and clinical experience at Prince Sultan Military Medical City. Combines hands-on clinical coverage in internal medicine and endocrine subspecialties with active contributions to clinical research, teaching programs, and medication safety initiatives. Skilled in optimizing complex therapy regimens, mentoring junior residents, and delivering evidence-based clinical presentations.

• Teaching and Learning Program (TLP) ( October 2023 - June 2024)

At the College of Pharmacy - Princess Nourah Bint Abdulrahman University

• Co-author in "Co-author in "Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes" Journal of Clinical Medicine (2024).
• Data collector in " Difference in the incidence of tuberculosis (TB) infection in patients Receiving Anti-Tumor Necrosis Factor (TNF)-a Monoclonal antibodies (MAbs) Infliximab and adalimumab."
• Co-author in "Sleep disorders in a Sample of students in Taif University, Saudi Arabia: The role of obesity, insulin resistance, anemia and high altitude " Diabetes & Metabolic Syndrome: Clinical Research & Reviews (2018).
• Co-author in "Sleep disorders in adolescents and young adults: Insights into types, relationship to obesity and high altitude and possible lines of management“ Diabetes & Metabolic Syndrome: Clinical Research & Reviews (2018)

• Updates In Treatment of H. Pylori Infection (April 2025)

Audience: Physicians, Clinical Pharmacists, and Pharmacy Residents.

• Successful care transitions for older people: a systematic review and meta-analysis of the effects of interventions that support medication continuity (Journal Club) (May 2024)

Audience: Clinical Pharmacists and Pharmacy Residents.

• Spontaneous Bacterial Peritonitis (SBP) (Feb 2024)

Audience: Physicians, Clinical Pharmacists, and Pharmacy Residents.

• Error-prone abbreviations and dose Expressions (Feb 2024)

Audience: Princess Norah Bint Abdulrahman University students.

• Empagliflozin in Patients Hospitalized for Acute Heart Failure-EMPULSE trial (Journal Club) (Feb 2024)

Audience: Clinical Pharmacists and Pharmacy Residents.

• Chronic Kidney Disease (CKD) (Jan 2024)

Audience: Clinical Pharmacists and Pharmacy Residents.

• Chronic Obstructive Pulmonary Disease (COPD) (June 2023)

Audience: Clinical Pharmacists and Pharmacy Residents.

• Drug Use Evaluation for Diabetes Mellitus Medications (Jan 2026)

Evaluated the utilization patterns of eighteen key diabetes medications across Inpatient and Outpatient settings over 12 months.

• Etelcalcetide Drug Evaluation (Dec 2023)

Conducted a comprehensive drug review and summarized relevant clinical data on efficacy, safety, and pharmacoeconomic data, and presented it to the P&T committee.

• Soliqua (Insulin glargine / lixisenatide) Drug Evaluation (Dec 2023)

Conducted a comprehensive drug review and summarized relevant clinical data on efficacy, safety, and pharmacoeconomic data, and presented it to the P&T committee.

• Ravulizumab Drug Evaluation (Nov 2023)

Conducted a comprehensive drug review and summarized relevant clinical data on efficacy, safety, and pharmacoeconomic data, and presented it to the P&T committee.

• Everolimus Drug Evaluation (Jan 2023)

Conducted a comprehensive drug review and summarized relevant clinical data on efficacy, safety, and pharmacoeconomic data, and presented it to the P&T committee.

• 2nd Place Award – Clinical Pharmacy Specialty Research Day Awards (Dec 2025)

Awarded 2nd place by the Saudi Commission for Health Specialties (SCFHS) for presenting research titled "Upadacitinib in Practice: Real-World Safety and Efficacy for Rheumatoid Arthritis in Saudi Patients".

• Outstanding Chief Resident in Clinical Pharmacy Award (Nov 2024)

Awarded by Prince Sultan Military Medical City (PSMMC) in recognition of exceptional leadership, clinical excellence, and administrative oversight as Chief Resident.

• Best Catch Award for Medication Safety (October 2019, June 2020).

Awarded by the Pharmaceutical Care Department for identifying and intercepting critical medication errors to ensure optimal patient safety.

• Highest Medication Clarification Record (MCR) Award (December 2019, June 2020).

Awarded by the Pharmaceutical Care Department for recording the highest volume of high-impact clinical intervention records per month.

• Multiple Sclerosis Day (2025)

A campaign to raise public awareness of Multiple Sclerosis and treatment options.

• World Hepatitis Day (2024)

A campaign to raise public awareness of viral hepatitis, the importance of screening, and treatment options.

• Smoking Cessation Campaign (2023)

An event that targeted the public to increase awareness about the harmful effects and medications to help in smoking cessation.

• Breastfeeding Campaign (2019)

A campaign to promote the benefits of breastfeeding to the public and educate them on using medications while breastfeeding.

• World Diabetes Day (2018)

Awareness activity at the National Guard’s primary care center, Taif.

• Diabetes, Know More (2018)

An event that targeted the public to increase awareness about diabetes.